Friday, July 10, 2026
🇺🇸 FDA

biotech

Kamada BioPharma Limited

Kamada BioPharma Limited at Fieldfisher LLP

Kamada BioPharma Limited clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

GB HQ
EMA registrant Type
Company details
Status
Public
HQ
GB
Programs
1
Drugs
3
Patents
0
All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Kamada BioPharma Limited projects

1 ClinicalTrials.gov programs sponsored by Kamada BioPharma Limited.

Kamada BioPharma Limited has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1 programs

Clinical programs

  1. KamadaAATInhaled008

    Kamada BioPharma Limited at Fieldfisher LLP

    Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Kamada BioPharma Limited have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.